NYXH Nyxoah

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares



REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), June 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  •  Share capital: EUR 5,904,962.41 
  •  Total number of securities carrying voting rights: 34,373,015 (all ordinary shares) 
  •  Total number of voting rights (= denominator): 34,373,015 (all relating to ordinary shares)  
  •  Number of rights to subscribe to securities carrying voting rights not yet issued: 
    •  100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);  
    •  400,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 400,500 securities carrying voting rights (all ordinary shares); and
    •  1,057,625 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,057,625 securities carrying voting rights (all ordinary shares); and
    •  698,875 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 698,875 securities carrying voting rights (all ordinary shares).  

*

*        *

Contact:

Nyxoah

David DeMartino, Chief Strategy Officer



Attachment



EN
28/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to...

Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module of its Premarket Approval (PMA) application for Genio to the U.S. Food and Drug Administration (FDA). Genio is a differe...

 PRESS RELEASE

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.  Share capital: EUR 5,904,962.41  Total number of securities carrying voting rights: 34,373,015 (all ordinary shares)  Total number of voting rights (= denominator):...

 PRESS RELEASE

Nyxoah to Participate in the Jefferies Global Healthcare Conference

Nyxoah to Participate in the Jefferies Global Healthcare Conference Nyxoah to Participate in the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – June 3, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 5 – 6, 2024 in New York. Olivier Taelman, Nyxoah’s Chi...

 PRESS RELEASE

Nyxoah Participera à la Conférence Jefferies Global Healthcare

Nyxoah Participera à la Conférence Jefferies Global Healthcare Nyxoah Participera à la Conférence Jefferies Global Healthcare Mont-Saint-Guibert, Belgique – 3 juin 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») opère dans le secteur des technologies médicales et se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La Société a annoncé aujourd’hui qu’elle participera à la conférence Jefferies Global Healthcare Conference, qui a lieu ...

 PRESS RELEASE

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.  Share capital: EUR 5,902,793.43  Total number of securities carrying voting rights: 34,360,390 (all ordinary shares)  Total number of voting rights (= denominator): ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch